Literature DB >> 31744890

Early-Life Predictors of Fetal Alcohol Spectrum Disorders.

Wendy O Kalberg1, Philip A May1,2,3, David Buckley1, Julie M Hasken2, Anna-Susan Marais3, Marlene M De Vries3, Heidre Bezuidenhout4, Melanie A Manning5, Luther K Robinson6, Margaret P Adam7, Derek B Hoyme8, Charles D H Parry3,9, Soraya Seedat3, Amy J Elliott10,11, H Eugene Hoyme12,11,13,14.   

Abstract

BACKGROUND AND OBJECTIVES: Fetal alcohol spectrum disorders (FASD) comprise the continuum of disabilities associated with prenatal alcohol exposure. Although infancy remains the most effective time for initiation of intervention services, current diagnostic schemes demonstrate the greatest confidence, accuracy, and reliability in school-aged children. Our aims for the current study were to identify growth, dysmorphology, and neurodevelopmental features in infants that were most predictive of FASD at age 5, thereby improving the timeliness of diagnoses.
METHODS: A cohort of pregnant South African women attending primary health care clinics or giving birth in provincial hospitals was enrolled in the project. Children were followed longitudinally from birth to 60 months to determine their physical and developmental trajectories (N = 155). Standardized protocols were used to assess growth, dysmorphology, and development at 6 weeks and at 9, 18, 42, and 60 months. A structured maternal interview, including estimation of prenatal alcohol intake, was administered at 42 or 60 months.
RESULTS: Growth restriction and total dysmorphology scores differentiated among children with and without FASD as early as 9 months (area under the receiver operating characteristic curve = 0.777; P < .001; 95% confidence interval: 0.705-0.849), although children who were severely affected could be identified earlier. Assessment of developmental milestones revealed significant developmental differences emerging among children with and without FASD between 18 and 42 months. Mothers of children with FASD were significantly smaller, with lower BMIs and higher alcohol intake during pregnancy, than mothers of children without FASD.
CONCLUSIONS: Assessment of a combination of growth, dysmorphology, and neurobehavioral characteristics allows for accurate identification of most children with FASD as early as 9 to 18 months.
Copyright © 2019 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2019        PMID: 31744890     DOI: 10.1542/peds.2018-2141

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

1.  The influence of maternal weight and alcohol exposure on infant physical characteristics and neurodevelopmental outcomes.

Authors:  Julie M Hasken; Linda S Adair; Stephanie L Martin; Amanda L Thompson; Anna-Susan Marais; Marlene M de Vries; Wendy O Kalberg; David Buckley; H Eugene Hoyme; Soraya Seedat; Charles D H Parry; Philip A May
Journal:  Curr Res Toxicol       Date:  2022-05-20

2.  The challenges and pitfalls of fetal alcohol spectrum disorders prevalence studies.

Authors:  Philip A May; Julie M Hasken; Melanie A Manning; H Eugene Hoyme
Journal:  Alcohol Clin Exp Res       Date:  2021-11-30       Impact factor: 3.455

3.  Fetal Alcohol Spectrum Disorder: Can We Change the Future?

Authors:  Svetlana Popova; Danijela Dozet; Larry Burd
Journal:  Alcohol Clin Exp Res       Date:  2020-03-30       Impact factor: 3.455

Review 4.  Institutionalized Children and the Risk of Fetal Alcohol Spectrum Disorder (FASD); A Primer for Clinicians, Adoption Staff and Parents.

Authors:  Gideon Koren; Asher Ornoy
Journal:  Glob Pediatr Health       Date:  2021-02-15

5.  Gestational age and birth growth parameters as early predictors of fetal alcohol spectrum disorders.

Authors:  Julie M Hasken; Anna-Susan Marais; Marlene de Vries; Belinda Joubert; Marise Cloete; Isobel Botha; Sumien Roux Symington; Wendy O Kalberg; David Buckley; Luther K Robinson; Melanie A Manning; Charles D H Parry; Soraya Seedat; H Eugene Hoyme; Philip A May
Journal:  Alcohol Clin Exp Res       Date:  2021-08-02       Impact factor: 3.928

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.